D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Morii, Takeshi ^a   Mochizuki, Kazuo ^a   Tajima, Takashi ^a   Ichimura, Shoichi ^a   Satomi, Kazuhiko ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHILD; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUSCULOSKELETAL DISEASE; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SARCOMA; SCHOOL CHILD; SURVIVAL RATE; UPREGULATION; BLOOD; BONE TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PROTEIN MULTIMERIZATION; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN MULTIMERIZATION; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80055025849     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-250     Document Type: Article

References (27)

1. The hypercoagulable state of malignancy: pathogenesis and current debate. Caine GJ, Stonelake PS, Lip GY, Kehoe ST, Neoplasia 2002 4 465 473 (Pubitemid 35417069)
2. Perioperative d-dimer levels in patients with musculoskeletal tumors. Morii T, Mochizuki K, Kotera M, Imakiire N, Moriwaki T, Satomi K, Open Orthop J 2008 2 130 132
3. Venous thromboembolism in the management of patients with musculoskeletal tumor. Morii T, Mochizuki K, Tajima T, Aoyagi T, Satomi K, J Orthop Sci 2010 15 810 815
4. Proximal deep vein thrombosis after hip replacement for oncologic indications. Nathan SS, Simmons KA, Lin PP, Hann LE, Morris CD, Athanasian EA, Boland PJ, Healey JH, J Bone Joint Surg Am 2006 88 1066 1070
5. Venous thromboembolism in patients with primary bone or soft-tissue sarcomas. Mitchell SY, Lingard EA, Kesteven P, McCaskie AW, Gerrand CH, J Bone Joint Surg Am 2007 89 2433 2439 (Pubitemid 350086333)
6. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, Imamura M, Cancer 2000 88 295 301 (Pubitemid 30051812)
7. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP, J Clin Invest 1994 94 1320 1327 (Pubitemid 24286478)
8. Osteosarcoma cell-calcium signaling through tissue factor-factor VIIa complex and factor Xa. Daubie V, De Decker R, Nicaise C, Pochet R, FEBS Lett 2007 581 2611 2615 (Pubitemid 46839099)
9. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M, Br J Cancer 2010 102 731 737
10. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y, Anticancer Res 2000 20 3031 3036
11. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, Nakamura S, Shiku H, Am J Hematol 2002 69 247 254 (Pubitemid 34259846)
12. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J, Int J Cancer 1998 75 780 786 (Pubitemid 28145828)
13. Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T, PLoS One 2010 5 15368
14. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V, Gynecol Oncol 1996 60 197 202 (Pubitemid 26058762)
15. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H, Surg Today 1998 28 373 378 (Pubitemid 28182584)
16. Plasma levels of prothrombin fragment F1+2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Kwon HC, Oh SY, Lee S, Kim SH, Han JY, Koh RY, Kim MC, Kim HJ, Jpn J Clin Oncol 2008 38 2 7 (Pubitemid 351248114)
17. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Batschauer AP, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LM, Fernandes AP, Gomes KB, Carvalho MG, Ann Oncol 2010 21 1267 1272
18. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, Paz L, Ma Y, Ward DC, Vogelzang NJ, Fink LM, Am J Clin Pathol 2010 134 964 969
19. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Antoniou D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, Dariotaki F, Chaimala D, Veslemes M, Lung Cancer 2006 53 205 210 (Pubitemid 43994226)
20. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, Hatipoglu ON, Caglar T, Clin Oncol (R Coll Radiol) 2007 19 494 498 (Pubitemid 47181178)
21. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Buccheri G, Torchio P, Ferrigno D, Cancer 2003 97 3044 3052 (Pubitemid 36676259)
22. The concept of curative margin in surgery for bone and soft tissue sarcoma. Kawaguchi N, Ahmed AR, Matsumoto S, Manabe J, Matsushita Y, Clin Orthop Relat Res 2004 419 165 172 (Pubitemid 38269688)
23. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS, N Engl J Med 2003 348 694 701 (Pubitemid 36237038)
24. Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. Tanaka K, Kawamoto H, Saito I, Yoshimura K, Fukuda H, Iwamoto Y, Jpn J Clin Oncol 2009 39 271 273
25. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, Furuse K, Minamizaki T, Kawaguchi N, Yamawaki S, J Orthop Sci 2009 14 397 404
26. Conditional survival of extremity soft-tissue sarcoma: results beyond the staging system. Parsons HM, Habermann EB, Tuttle TM, Al-Refaie WB, Cancer 2011 117 1055 1060
27. Staging of primary malignancies of bone. Heck RK Jr, Peabody TD, Simon MA, CA Cancer J Clin 2006 56 366 375 (Pubitemid 44903910)